Iron Sucrose Administration in Reduced Kidney Function

Administration Protocol by CKD Population

• The American Journal of Kidney Diseases recommends administering 100 mg of iron sucrose to adult hemodialysis patients during each consecutive hemodialysis session, typically early in the session, with a total treatment course of 1000 mg over 10 weeks 1, 2
• For maintenance therapy after achieving target iron levels, the Praxis Medical Insights guideline suggests continuing 25-125 mg weekly in adult hemodialysis patients 1
• The American Journal of Kidney Diseases recommends that doses larger than 100 mg given at one time are not recommended for hemodialysis patients to minimize arthralgias and myalgias 2

Key Safety Considerations

• Iron sucrose does not require a test dose, unlike iron dextran, which carries an anaphylaxis risk, as stated by the American Journal of Kidney Diseases and Praxis Medical Insights 3, 4
• The Clinical Nutrition journal reports that iron sucrose has a superior safety profile with fewer adverse effects than iron dextran 5
• Research demonstrates that 200-300 mg doses of iron sucrose over 2 hours are safe, while 400 mg doses showed adverse reactions in 2 of 35 patients, and 500 mg doses caused reactions in 8 of 22 patients 5

Monitoring Parameters

• The Praxis Medical Insights guideline recommends measuring iron parameters without interrupting therapy for doses ≤100-125 mg weekly, waiting at least 7 days for doses of 200-500 mg, and waiting at least 2 weeks for doses ≥1000 mg 1
• The American Journal of Kidney Diseases and Praxis Medical Insights recommend maintaining transferrin saturation (TSAT) ≥20%, serum ferritin ≥100 ng/mL for non-dialysis patients, and ≥200 ng/mL for hemodialysis patients 2, 4

Clinical Context and Rationale

• The American Journal of Kidney Diseases states that oral iron usually cannot maintain adequate iron stores in hemodialysis patients treated with erythropoietin due to high iron losses and functional iron deficiency 2
• The Praxis Medical Insights guideline reports that among early non-responders to oral iron, only 21% respond to additional oral therapy versus 65% who respond to IV iron 4

Special Populations and Contraindications

• The Praxis Medical Insights guideline recommends withholding IV iron during active bacteremia, but it can be administered during inflammation 1
• The Praxis Medical Insights guideline also suggests that IV iron may be more effective than oral iron in inflammatory conditions like inflammatory bowel disease due to hepcidin-mediated inhibition of oral iron absorption 1